EBV-NK cells interactions and lymphoproliferative disorders

Leukemia and Lymphoma

Volumn 29, Issue 5-6, 1998, Pages 491-498

  Kanegane, Hirokazu ^a   Yachie, Akihiro ^b   Miyawaki, Toshio ^a   Tosato, Giovanna ^c  

^a UNIVERSITY OF TOYAMA   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Esptein Barr virus; Latency; Lymphoproliferative disorder; Natural killer cells

Indexed keywords

CELL NUCLEUS ANTIGEN; MEMBRANE PROTEIN;

CELL INTERACTION; CELL LINE; EPITHELIUM CELL; EPSTEIN BARR VIRUS; GENE EXPRESSION; HODGKIN DISEASE; HUMAN; LYMPHOPROLIFERATIVE DISEASE; NASOPHARYNX CARCINOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; T CELL LYMPHOMA; VIRUS INFECTION;

EID: 0031863940     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199809050908     Document Type: Review

References (26)

1. Kieff, E. and Liebowitz, D. (1990). Epstein-Barr virus and its replication. In: Fields Virology, B. N. Fields and D. M. Knipe (eds.), pp 1889-1920, (Raven press, New York).
2. Tosato, G., Taga, K., Angiolillo, A. L., et al. (1996). Epstein-Barr virus as an agent of haematological disease. Bailliere's Clin. Haematol., 8, 165-199.
3. McClain, K. L., Leach, C. T., Jenson, H. B., et al. (1995). Association of Epstein-Barr virus with leiomyosarcomas in young people with AIDS. N. Engl. J. Med., 332, 12-18.
4. Lee, E. S., Locker, J., Nalesnik, M., et al. (1995). The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N. Engl. J. Med., 332, 19-25.
5. Klein, G. (1994). Epstein-Barr virus strategy in normal and neoplastic B cells. Cell, 77, 791-793.
6. Oshimi, K. (1996). Lymphoproliferative disorders of natural killer cells. Int. J. Hematol., 63, 279-290.
7. Jaffe, E. S. (1996). Classification of natural killer (NK) cell and NK-like T-cell malignancies. Blood, 87, 1207-1210.
8. Kanegane, H., Wang, F. and Tosato, G. (1996). Virus-cell interactions in a natural killer-like cell line from a patient with lymphoblastic lymphoma. Blood, 88, 4667-4675.
9. Spits, H., Lanier, L. L. and Philips, J. H. (1995). Development of human T and natural killer cells. Blood, 85, 2654-2670.
10. Semenzato, G., Zambello, R., Starkebaum, G., et al. (1997). The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis. Blood, 89, 256-260.
11. Kawa-Ha, K., Ishihara, S., Ninomiya, T., et al. (1989). CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA. J. Clin. Invest., 84, 51-55.
12. Fukunaga, Y., Asano, T., Takehana, J., et al. (1994). CD3-negative lymphoproliferative disease of granular lymphocytes in a girl with an unusual pattern of anti-Epstein-Barr virus antibodies. Eur. J. Pediatr., 153, 894-897.
13. Shimodaira, S., Ishida, F., Kobayashi, H., et al. (1995). The detection of clonal proliferation in granular lymphocyte-proliferative disorders of natural killer cell lineage. Brit. J. Haematol., 90, 578-584.
14. Kanegane, H., Wada, T., Nunogami, K., et al. (1996). Chronic persistent Epstein-Barr virus infection of natural killer cells and B cells associated with granular lymphocytes expansion. Brit. J. Haematol., 95, 116-122.
15. Jaffe, E. S., Chan, J. K. C., Su, I. J., et al. (1996). Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas. Am. J. Surg. Pathol., 20, 103-111.
16. + T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas. Blood, 87, 1446-1473.
17. + immunophenotype and polymorphic-reticulosis morphology. Int. J. Cancer, 70, 9-13.
18. Tosato, G., Sgadari, C., Taga, K., et al. (1994). Regression of experimental Burkitt's lymphoma induced by Epstein-Barr virus-immortalized human B cells. Blood, 83, 776-784.
19. Hart, D. N. J., Baker, B. W., Inglis, M. J., et al. (1992). Epstein-Barr viral DNA in acute large granular lymphocyte (natural killer) leukemic cells. Blood, 79, 2116-2123.
20. Loughran, T. P. Jr., Zambello, R., Ashley, R., et al. (1993). Failure to detect Epstein-Barr virus DNA in peripheral blood mononuclear cells of most patients with large granular lymphocyte leukemia. Blood, 81, 2723-2727.
21. - myeloid/natural killer cell acute leukemia: a previous unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3. Blood, 84, 244-255.
22. Yodoi, J., Teshigawara, K., Nikaido, T., et al. (1985). TCGF (IL 2)-receptor inducing factor(s) I. regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J. Immunol., 134, 1623-1630.
23. Yoneda, N., Tatsumi, E., Kawano, S., et al. (1992). Detection of Epstein-Barr virus genomes in natural-killer-like cell line, YT. Leukemia, 6, 136-141.
24. Kaneko, T., Fukuda, J., Yoshihara, T., et al. (1995). Nasal natural killer (NK) cell lymphoma: report of a case with activated NK cells containing Epstein-Barr virus and expressing CD21 antigen, and comparative studies of their phenotype and cytotoxicity with normal NK cells. Brit. J. Haematol., 91, 355-361.
25. Chiang, A. K. S., Tao, Q., Srivastava, G., et al. (1996). Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr latency as nasopharyngeal carcinoma and Hodgkin's disease. Int. J. Cancer, 68, 285-290.
26. Papadopoulos, E. B., Ladanyi, M., Emanuel, D., et al. (1994). Infusion of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med., 330, 1185-1191.